Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SNS-101, a conditionally active VISTA-blocking antibody, paving the way for the Company to conduct a Phase 1/2 clinical trial in patients with solid tumors.
https://finance.yahoo.com/news/sensei-biotherapeutics-announces-ind-clearance-113000293.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.